References
- Leffler DA, Lamont JT. Clostridium difficile infection. The New England Journal of Medicine 2015;372:1539–1548.2587525910.1056/NEJMra1403772
- Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy N. Role of the normal gut microbiota. World Journal of Gastroenterology 2015, 8787–8803.26269668
- Guarner F, Malagelada J. Gut flora in health and disease. The Lancet 2003. 361(9356): 512–519.10.1016/S0140-6736(03)12489-0
- Heinlen L, Ballard JD. Clostridium difficile infection. The American Journal of the Medical Sciences 2010;340(3): 247–252.10.1097/MAJ.0b013e3181e939d820697257
- Leffler DA, Lamont JT. Treatment of Clostridium difficile-associated disease. Gastroenterology 2009; 136(6):1899–1912.10.1053/j.gastro.2008.12.070
- Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Québec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466–472.10.1503/cmaj.1041104
- Benea S, Popescu GA, Badicut I, Florea D, Petrache D, Gavriliu L, et al. Clostridium difficile infections hospitalized in Romanian Institute of Infectious Diseases during the first three months of 2012. Poster Presentation, 4th International C. difficile Symposium, September 20-22, Bled, Slovenia.
- Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. The American Journal of Gastroenterology 2012;107:1001–1110.10.1038/ajg.2012.17922710578
- Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. The American Journal of Gastroenterology 2007;102:2047–2056.10.1111/j.1572-0241.2007.01275.x17509031
- Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut 2016;65(5):740–748. doi: 10.1136/gutjnl-2015-310376. Epub https://emedicine.medscape.com/article/186458-overview[Accessed 2nd March, 2019].10.1136/gutjnl-2015-31037626657899
- McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infection Control & Hospital Epidemiology 2007; 28(2):140–145 (ISSN: 0899-823X).10.1086/511798
- Popescu GA, Szekely E, Codita I, Talapan D, Serban R, Ruja G. Ghid de diagnostic, tratament si prevenire a infectiilor determinate de Clostridium difficile Bucharest 2016. Available from: http://mainicurateinspitale.ro/wp-content/uploads/2016/08/Ghid-diagnostic-tratament-si-prevenire-Clostridium-difficile.pdf[Accessed 2nd March, 2019].
- Pepin J. Improving the treatment of Clostridium difficile-associated disease: where should we start? Clinical Infectious Diseases 2006, 43(5):553–555.10.1086/506357
- Musgrave CR, Bookstaver PB, Sutton SS, Miller AD. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. The International Journal of Infectious Diseases 2011;15:e438–e448.10.1016/j.ijid.2011.03.017
- Brown KA et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrobial Agents and Chemotherapy. 2013; 57:2326. Available from: http://dx.doi.org/10.1128/AAC.02176-1210.1128/AAC.02176-1223478961
- Deshpande A et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. Journal of Antimicrobial Chemotherapy 2013 Apr 25; [e-pub ahead of print]. Available from: http://dx.doi.org/10.1093/jac/dkt129
- Obuch-Woszczatyński P, Dubiel G, Harmanus C, Kuijper E, Duda U, Wultańska D, van Belkum A, Pituch H. Emergence of Clostridium difficile infection in tuberculosis patients due to a highly rifampicin-resistant PCR ribotype 046 clone in Poland. European Journal of Clinical Microbiology & Infectious Diseases 2013; 32:1027–1030. Available from: doi: 10.1007/s10096-013-1845-5.10.1007/s10096-013-1845-5
- Lee YM, Huh KC, Yoon SM, Jang BI, Shin JE, Koo HS, et al. Incidence and clinical outcomes of Clostridium difficile infection after treatment with tuberculosis medication. Gut and Liver 2016; 10(2): 250–254.10.5009/gnl14435
- Wipperman MF, Fitzgerald DW, Juste MAJ, Taur Y, Namasivayam S, Sher A, et al. Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed. Scientific Reports 2017;7:10767. Published online 2017 Sep 7. doi: 10.1038/s41598-017-10346-6.10.1038/s41598-017-10346-628883399
- Kullin BR, Reid S, Abratt V. Clostridium difficile in patients attending tuberculosis hospitals in Cape Town, South Africa, 2014–2015. African Journal of Laboratory Medicine 2018;7(2): a846. Available from: https://doi.org/10.4102/ajlm.v7i2.846
- Legenza L, Barnett S, Rose W, Bianchini M, Safdar N, Coetzee R. Epidemiology and outcomes of Clostridium difficile infection among hospitalised patients: results of a multicentre retrospective study in South Africa. BMJ Global Health 2018;3:e000889. doi:10.1136/bmjgh-2018-000889.10.1136/bmjgh-2018-000889
- Freedberg DE, Salmasian H, Cohen B, Abrams JA, Larson EL. Receipt of antibiotics in hospitalized patients and risk for Clostridium difficile infection in subsequent patients who occupy the same bed. JAMA Internal Medicine 2016, 176(12): 1801–1808. doi:10.1001/jamainternmed.2016.6193.10.1001/jamainternmed.2016.6193